US FDA News: FDA approves first treatment for all genotypes of hepatitis C in pediatric patients

FDA approved Mavyret (glecaprevir and pibrentasvir) tablets to treat all six genotypes of hepatitis C virus (HCV) in children ages 12 to 17.
Read more: FDA approves first treatment for all genotypes of hepatitis C in pediatric patients